Phathom Pharmaceuticals (PHAT) Equity Ratio (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Equity Ratio data on file, last reported at 1.1 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 1.1, up 3.98% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.1 (up 3.98% YoY), and the FY2025 annual result was 1.69, down 152.25% from the prior year.
• Equity Ratio climbed to 1.1 in Q1 2026 per PHAT's latest filing, from 1.69 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.26 in Q1 2022 and troughed at 1.76 in Q3 2025.
• A 5-year average of 0.64 and a median of 0.48 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio surged 302.54% in 2023, then tumbled 1202.54% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.45 in 2022, then soared by 61.27% to 0.18 in 2023, then plunged by 281.25% to 0.67 in 2024, then plunged by 152.25% to 1.69 in 2025, then jumped by 34.69% to 1.1 in 2026.
• Business Quant data shows PHAT's Equity Ratio at 1.1 in Q1 2026, 1.69 in Q4 2025, and 1.76 in Q3 2025.